Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Ranibizumab, Bevacizumab, and Aflibercept in nAMD
NCT02118831Phase 2Completed
- Sponsor
- California Retina Consultants
- Start
- Mar 2012
- Primary completion
- Feb 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of ranibizumab, bevacizumab and aflibercept in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO), sponsored by California Retina Consultants. Started Mar 2012; status: completed.
02
Drugs
ranibizumabbevacizumabaflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT02118831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118831.